论文部分内容阅读
目的探讨度洛西汀对恶性肿瘤患者伴发抑郁障碍的临床疗效及安全性。方法 60例肿瘤伴发抑郁的患者,随机分为两组,每组30例,两组患者均接受常规抗肿瘤治疗,研究组在此基础上联合度洛西汀治疗,观察8周。于治疗前及治疗2周、4周及8周末采用汉密尔顿抑郁量表评定抑郁情绪,副反应量表评定不良反应。结果治疗8周末研究组抑郁情绪改善率为76.7%,未治疗组为26.7%,研究组显著高于未治疗组(P<0.01);研究组汉密尔顿量表评分较未治疗组显著下降(P<0.05);两组不良反应无差异性。结论度洛西汀治疗肿瘤患者伴发抑郁障碍效果显著,安全性高。
Objective To investigate the clinical efficacy and safety of duloxetine in patients with malignant tumor accompanied by depression. Methods Sixty patients with tumor-associated depression were randomly divided into two groups (n = 30 in each group). Both groups received routine anti-tumor therapy. The study group was treated with duloxetine for 8 weeks. The depression was assessed by Hamilton Depression Rating Scale before treatment, 2 weeks, 4 weeks and 8 weeks after treatment. The adverse reaction was assessed by the side effects scale. Results At the end of the 8th week, the improvement rate of depression was 76.7% in the study group and 26.7% in the untreated group, which was significantly higher in the study group than in the untreated group (P <0.01). The Hamilton scale score in the study group was significantly lower than that in the untreated group (P < 0.05); no adverse reactions between the two groups. Conclusion Duloxetine treatment of cancer patients with depression is significant and safe.